Results 191 to 200 of about 447,481 (255)

Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: mechanisms and clinical implications from a heart-liver metabolic axis perspective. [PDF]

Front Pharmacol
Wu X, Ma Y, Yin X, Liu J, Zhang Y.
europepmc   +1 more source

Lactate‐Induced K370 Lactylation of STING Inhibits STING‐TBK1 Signaling and Dampens Anti‐Tumor Immunity

Advanced Science, EarlyView.
Lactate accumulation in glioblastoma drives lactylation of STING at lysine 370, a primate‐conserved residue. K370 lactylation weakens STING‐TBK1 binding, destabilizes STING, and disrupts ER‐to‐Golgi trafficking, blunting type I interferon signaling. LDHA inhibition reverses K370 lactylation and improves the antitumor efficacy of STING agonism combined ...
Yueyao Wu, Jingzhe Wang, Xu Chen, Yuntong Yang, Ping Wei, Han Xie, Honghao Wang, Chunyu Zhang, Siyi Xu, Qi Wang, Chunlong Zhong, Jing Zhang   +11 more
wiley   +1 more source

Correction to: Cardiovascular pharmacotherapy in 2025. [PDF]

Eur Heart J Cardiovasc Pharmacother
europepmc   +1 more source

The Association Between Glucagon-like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Thoracic Aortic Aneurysm. [PDF]

Diagnostics (Basel)
Raslan MA, Abdul Nabi H, Dreher L, Al Osta S, De Sousa Barzon Serra V, Ayoub C, El Masry H, Shamoun FE.   +7 more
europepmc   +1 more source

Engineering CAR‐Macrophages With Advanced Delivery Systems for Tissue Repair

Advanced Science, EarlyView.
This review highlights how engineered macrophages equipped with chimeric antigen receptors (CAR) guide tissue repair by recognizing disease‐related targets, clearing harmful cells, and reshaping local immune environments. It summarizes macrophage biology, CAR design, delivery platforms, and functionalization strategies, and discusses emerging ...
Yixin Zhang, Jintian Yu, Liang Yuan, Ziliang Fu, Yiming Yao, Lingna Chen, Shixiong Chen, Aikemu Ainiwaer, Xiaolin Cui   +8 more
wiley   +1 more source

Disrupting clinical inertia: Personalizing cardiovascular risk to transform cardiometabolic care in the real world. [PDF]

Am J Prev Cardiol
Abushamat LA, Reusch JEB, Ballantyne CM.
europepmc   +1 more source

Revisiting Glycemic Control Targets: Survival Outcomes by Glycated Hemoglobin Levels Among Patients With Diabetes Under Contemporary Antidiabetic Therapy. [PDF]

J Am Heart Assoc
Lin DS, Lo HY, Lee JK.
europepmc   +1 more source

Pharmacological safety and real-world efficacy of the potassium-competitive acid blocker fexuprazan in cardiovascular patients receiving antithrombotic therapy: a prospective cohort study (FEXGARD). [PDF]

Front Pharmacol
Hwang YM, Kim SJ, Yoo M.
europepmc   +1 more source

[Modern cardiovascular agents].

Farmatsevtychnyi zhurnal, 1978
openaire   +1 more source